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Sup Fig. 1. Neutrophil activation and function are unaltered by short term stimulation 
with CAF-derived factors. (A) Characterization of skin, lung and pancreatic FBs and CAFs 
by flow cytometry showing that the cells express the classic CAF markers (Thy1, Podoplanin, 
PDGFR) on the surface and lack expression of tumor cell (EpCAM) and immune cell (CD45) 
markers. (B) Quantification of neutrophil death after treatment with FB CMed, CAF CMed from 
lung or pancreas or PMA based on expression of Annexin V and 7-AAD by flow cytometry. 
(C) Quantification of CD11b, CD18 and CD62L expression on neutrophils after treatment with 
lung FB or CAF CMed with and without simulation with LPS by flow cytometry. (D) 
Quantification of ROS production by neutrophils after treatment with lung CAF CMed or PMA 
based on the levels of DCFDA by flow cytometry. (E) The phagocytic capacity of neutrophils 
after lung CAF CMed or PMA treatment based on uptake of fluorescent 1µm beads assessed 
by flow cytometry. (F) Representative confocal image of neutrophils (arrows) and NETs 
(arrowheads) in murine lung cancer, scale bar 50µm. Data are mean ± SEM; * = p<0.05, ** = 
p<0.01 and *** = p<0.001 using (C) paired t-test (comparing each condition) and (D-E) one-
way ANOVA with a Dunnett post hoc test. Assays were performed on (A) n=1, (B) n=2, (C) 
n=4, (D) n=8 (Untreated and CAF CMed) and n=5 (PMA), (E) n=5 and (F) Representative of 
























Sup Fig. 2. CAF-induced NETosis is a ROS-dependent, autophagy independent 
response. (A) Schematic of NETosis assay (B) Representative phase contrast images of 
SYTOX green stained dead neutrophils and NETs after 3h treatment with PMA or pancreatic 
CAF CMed. Inset; zoomed image of a NET (green haze) outlined with a dashed white line. 
Quantification of the relative NET coverage of neutrophils treated with lung CAF CMed with 
or without treatment with (C) Chloroquine (Cl), (D) Diphenyleneiodonium (DPI), (E) Trolox and 
(F) Vitamin C. Data are mean ± SEM; * = p<0.05, ** = p<0.01 and *** = p<0.001 using (C-F) 
one-way ANOVA with a Tukey post hoc test. Assays were performed on (B) Representative 
of n=7, (C) n=5, (D) n=4, (E-F) n=2 (in triplicate) independent experiments. Scale bars 





































































































































































Sup Fig. 3. CAF-derived factors drive NETosis systemically. (A) Quantification of the 
percentage death of bone marrow neutrophils taken from mice with pancreatic, lung or skin 
tumors. (B) Quantification of percentage death of bone marrow neutrophils taken from wild 
type mice intravenously infused with pancreatic or lung FB or CAF CMed 24h before 
performing the NETosis assay.  (C) Quantification of percentage death and relative number 
of bone marrow neutrophils taken from mice intravenously infused with lung CAF CMed with 
or without pre-treatment with Cl-amidine for 24h. Data are mean ± SEM; * = p<0.05, ** = 
p<0.01 and *** = p<0.001 using (A and C) paired t-test and (B) one-way ANOVA with Dunnett 
post hoc test. Assays were performed on (A) n=4 (in duplicate), n=7 (in quadruplet) and n=7 
for pancreatic, lung and skin tumor bearing mice respectively, (B) n=8, 4 and 8 (Pancreatic for 
basal media, FB CMed and CAF CMed treatment, respectively. All performed in triplicate) and 
n=9, 6 and 9 (Lung for basal media, FB CMed and CAF CMed treated, respectively. Performed 
in duplicate for basal media and CAF CMed and only a single time for FB CMed treated), (C) 







































































































































































































































































































































































































































Sup Fig. 4. Treatment of skin tumor bearing mice with a broad-spectrum PAD inhibitor 
reduces tumor growth. (A) Relative volume of skin tumors on mice treated with vehicle or 
Cl-amidine over 8d. (B) Flow cytometric analysis of the percentage immune cells (CD45+), 
myeloid cells (CD11b+), macrophages (F4/80+) and neutrophils (Ly6G+) in the tumors treated 
with Cl-amidine. (C) Flow cytometric analysis of CAF populations in the tumors treated with 
Cl-amidine based on the percentage Thy1, Podoplanin and PDGFRα positive cells. (D) The 
levels of clotting factors (fibrinogen and von Willerbrand factor; vWF) in the plasma of skin 
tumor bearing mice treated with vehicle or Cl-amidine. (E) Flow cytometric analysis of CAF 
populations in the tumors treated with GSK484 based on the percentage Thy1, Podoplanin 
and PDGFRα positive cells. (F) Representative phase contrast images of skin tumor cells after 
treatment with vehicle, 100µM Cl-amidine or 10µM GSK484 over 48h. Bar graphs are mean 
± SEM; * = p<0.05 and ** = p<0.01 using (A) a Mann-Whitney test. Box and whiskers graph-
line: median, box: upper and lower quartiles, whiskers: maxima and minima. Assays were 
performed on (A and B) n=7 (Vehicle) and n=8 (Cl-amidine), (C) n=8 (Vehicle) and n=6 (Cl-
amidine) (D) n=6 (both conditions) for Fibrinogen and n=7 (both conditions) for vWF, (E) n=8 
(Vehicle) and n=4 (GSK484) in duplicate for all markers, (F) n=3 (Vehicle) and n=2 (Cl-amidine 








































































































































































































































































































Sup Fig. 5. Treatment of pancreatic tumor bearing mice with a broad-spectrum PAD 
inhibitor has no effect on tumor growth. (A) Schematic of Cl-amidine treatment regime for 
pancreatic tumor bearing mice. (B) Relative cross-sectional area (CSA) and diameter of 
tumors treated with vehicle or Cl-amidine over 8d. (C) The levels of clotting factors (fibrinogen 
and von Willerbrand factor; vWF) in the plasma of pancreatic tumor bearing mice treated with 
vehicle or Cl-amidine. (D) Flow cytometric analysis of the percentage immune cells (CD45+), 
myeloid cells (CD11b+), macrophages (F4/80+) and neutrophils (Ly6G+) in the tumor. (E) Flow 
cytometric analysis of CAF populations in the tumor based on the percentage Thy1, 
Podoplanin and PDGFRα positive cells. Assays were performed on n=4 independent 
experiments. Bar graphs are mean ± SEM. Box and whiskers graph-line: median, box: upper 






































Sup Fig. 6. Inhibiting t-NETosis suppresses growth of subcutaneous (s.c.) pancreatic 
tumors in vivo. (A) Schematic of GSK484 treatment regime for s.c. pancreatic tumor-bearing 
mice. (B) Relative endpoint volume of s.c. pancreatic tumors in mice treated with vehicle or 
GSK484 after 8d (volume compared to the pre-treatment tumor volume – indicated by dotted 
line). Red dots represent mice reaching legal endpoint prior to the end of the 8d treatment 
(within 5-7d of treatment). (C) Representative confocal images of neutrophils and CAFs in 
vehicle or GSK484 treated s.c. pancreatic tumors (MPO, green; PDPN, blue; DAPI, white). 
(D) Representative confocal images of NETting neutrophils and CAFs in vehicle or GSK484 
treated s.c. pancreatic tumors (MPO, green; CitH3, red; PDPN, blue; DAPI, white). Scale bars 
are 50µm. (E) Quantification of relative NET coverage, percentage death and relative number 
of bone marrow neutrophils taken from mice with s.c. pancreatic tumors. (F) Relative endpoint 
volume of s.c. pancreatic tumors in PAD4-/- or WT littermate mice after 8d (compared to the 
tumor volume at day 10 post-induction indicated by dotted line). Red dots indicate mice 
reaching legal endpoint prior the end of the 8d (within 5-7d). Data are mean ± SEM; * = p<0.05, 
** = p<0.01 and *** = p<0.001 using (B, E-F) unpaired t-test. Assays were performed on (B) 
n=8 mice, (C-D) Representative of n=3, (E) n=2 or 3 vehicle and GSK484 treated mice 















































Sup Fig. 7. Enlarged heatmap for differentially secreted proteins in pancreatic FB and 
CAF CMed analyzed by mass spectrometry. The relative intensity of each protein is 












































Sup Fig. 8. Amyloid β is sufficient to drive NETosis in vitro. (A) Quantification of the 
relative NET coverage and percentage death of neutrophils treated with pancreatic CAF CMed 
with or without a fibronectin inhibitor (FNi). (B) Log2(reads per kilobase transcript per million 
map reads; RPKM+1) expression of the app gene in pancreatic (pan) CAFs normalized to 
pancreatic (pan) stellate cells from publicly available data (2). (C) Quantification of the relative 
NET coverage and percentage death of neutrophils treated with recombinant Amyloid α (Aα), 
recombinant Amyloid β (Aβ) or PMA for 3h. Data are mean ± SEM; * = p<0.05, ** = p<0.01 
and *** = p<0.001 using (A) paired t-test and (C) one-way ANOVA with a Dunnett post hoc 
test. Assays were performed on (A) n=2 (in duplicate), (C) n=3 (in duplicate or triplicate) 
independent experiments. 
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Sup Fig. 9. Inhibition of Amyloid β secretion by CAFs suppresses NETosis. (A) 
Quantification of percentage death of neutrophils treated with pancreatic and lung CAF CMed 
generated with or without 24h pre-treatment of the CAFs with β-secretases 1 and 2 (BACE1-
2) inhibitor.(B) Quantification of the percentage death of bone marrow neutrophils taken from 
wild type mice 24h after intravenous infusion with pancreatic CAF CMed taken from cells pre-
treated with or without BACE1-2 inhibitor for 24h or recombinant Amyloid β. (C) Quantification 
of cell death after 3h treatment with pancreatic CAF CMed with or without CD11b or TLR2 
blocking antibodies. (D) Representative confocal images showing neutrophils 
(myeloperoxidase (MPO; in green), CAFs (podoplanin, in blue) and counterstained with DAPI 
(in white) of orthotopically implanted B16.F10 tumor cells with vehicle, CAF CMed or 
recombinant Amyloid β treatment. Data are mean ± SEM; * = p<0.05, ** = p<0.01 and *** = 
p<0.001 using (A-B) one-way ANOVA with a Tukey post hoc test and (C) one-way ANOVA 
with a Dunnett post hoc test. Assays were performed on (A) n=6 (in triplicate), (B) n=7 (in 
duplicate or triplicate), (C) n=3 (in triplicate) and (D) Representative of n=3 independent 












































Sup Fig. 10. Amyloid β driven t-NETosis is conserved in the human disease. (A) 
Representative confocal images of NETting neutrophils and CAFs in a human brain 
metastasis (MPO, green; CitH3, red; podoplanin, blue; DAPI, white). (B) Quantification of 
Amyloid β in plasma from melanoma patients and healthy controls. Data are mean ± SEM. 
Assays were performed on (A) n=1 brain metastasis and (B) n=10 (Normal) and n=19 
(Melanoma) independent experiments. Scale bars are 50µm. 
 
